Format: Abstract

Future Cardiol. 2017 May;13(3):219-227. doi: 10.2217/fca-2016-0063. Epub 2017 Jun 6.

Elevation of plasma oncostatin M in heart failure.

Gruson D[1,2], Ferracin B[2], Ahn SA[3], Rousseau MF[3].

Author information

Abstract

AIM: Oncostatin M (OSM) is an inflammatory cytokine of the gp130 family. OSM could participate in adverse cardiovascular remodeling through regulation of FGF23.

MATERIALS & METHODS: OSM levels were determined in 80 heart failure patients with reduced left ventricular ejection fraction (HFrEF).

RESULTS: OSM levels are significantly increased in HFrEF patients compared with healthy subjects. We have also demonstrated that, in HFrEF patients, plasma OSM levels are correlated to parathyroid hormone PTH(1-84) and $1,25(OH)_2D$, two other biomarkers related to bone and mineral metabolism and associated to adverse cardiovascular outcomes.

CONCLUSION: OSM concentrations are elevated in HFrEF patients and could interplay with parathyroid hormone and vitamin D impacting cardiovascular function. Nevertheless, the prognostic value of OSM testing appears limited.

KEYWORDS: FGF-23; biomarker; heart failure; oncostatin; vitamin D

PMID: 28585906 DOI: 10.2217/fca-2016-0063

LinkOut - more resources

PubMed Commons

PubMed Commons home

0 comments

How to join PubMed Commons